Entellus Medical

2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/14/17Entellus Medical to Participate in Upcoming Investor Conferences
PLYMOUTH, Minn., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced the Company plans to participate in two upcoming investor conferences. November 28, 2017 at 1:30pm ET, Entellus management is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference in New York, NY.  Interested parties can access the live and archived webcast at http://www.entell... 
11/13/17Anthem Inc. Issues Positive Coverage Decision for Balloon Sinus Dilation
Anthem Insurance Plans Covering 40 Million Lives Now Provide Reimbursement for XprESS™ ENT Dilation System for Treating Chronic and Recurrent Acute Sinusitis PLYMOUTH, Minn., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that Anthem, Inc. now covers balloon sinus dilation (BSD) for the treatment of chronic and recurrent acute sinusitis. Anthem, the largest member of ... 
11/01/17Entellus Medical Announces Third Quarter 2017 Financial Results
PLYMOUTH, Minn., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering less invasive ENT products, today reported its financial results for the quarter ended September 30, 2017.  Recent Highlights and Accomplishments Revenue of $23.3 million in the third quarter of 2017, an increase of 30.5% over same quarter last year, including $3.1 million as a result of the acquisition of Spirox, Inc., which closed on July 13th ... 
10/30/17Entellus Announces Long-Term Data Confirming the Durable Relief of Nasal Obstruction Symptoms with Latera® from Spirox®
18 and 24-Month Data Reinforces Clinical Benefits Without Cosmetic Downside PLYMOUTH, Minn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL) today announced data from its first-in-human study of the Latera® absorbable nasal implant from Spirox®. The 18 and 24-month data demonstrate that patients who received Latera had significant improvement in nasal obstruction symptoms with no negative cosmetic changes. The results were selected for presentation at the 2017 Annual Co... 
10/18/17Entellus Medical to Report Third Quarter 2017 Financial Results November 1, 2017
Conference call scheduled for Wednesday, November 1, 2017 at 3:30 p.m. CT / 4:30 p.m. ET PLYMOUTH, Minn., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that it will release financial results for the third quarter 2017 after the close of trading on Wednesday, November 1, 2017. The company’s management team will host a corresponding conference call beginning at 3:30 p.... 
08/08/17Entellus Medical Announces New Employee Inducement Option Grants
PLYMOUTH, Minn., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that the Compensation Committee of the Board of Directors of Entellus granted stock options covering an aggregate of 325,500 shares of Entellus common stock to 42 persons newly employed by Entellus as a result of the Spirox, Inc. acquisition. The stock options were granted effective as of August 4, 2017... 
08/03/17Entellus Medical Announces Second Quarter 2017 Financial Results
PLYMOUTH, Minn., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis, nasal airway obstruction and persistent Eustachian tube dysfunction, today reported its financial results for the quarter ended June 30, 2017.  Recent Highlights and Accomplishments Revenue of $22.1 million ... 
07/26/17Entellus Medical to Present at the Canaccord Genuity Annual Growth Conference
PLYMOUTH, Minn., July 26, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the less invasive treatment of chronic and recurrent sinusitis, nasal airway obstruction, and persistent Eustachian tube dysfunction, today announced the Company plans to participate in the 37th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA. Entellus Medical’s ... 
07/20/17Entellus Medical to Report Second Quarter 2017 Financial Results August 3, 2017
Conference call scheduled for Thursday, August 3, 2017 at 3:30pm CT / 4:30pm ET PLYMOUTH, Minn., July 20, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for less invasive treatment of patients suffering from chronic and recurrent sinus and nasal airway conditions, today announced that it will release its financial results for the second quarter 2017 after the... 
07/07/17Entellus Medical Announces Definitive Agreement to Acquire Spirox
Acquisition Adds Innovative and Minimally Invasive Treatment For Nasal Airway Obstruction – Significantly Expanding Office and Operating Room Based ENT Opportunities  Announces Preliminary Second Quarter 2017 Revenue Results and Updates 2017 Outlook  Conference Call Today at 8:30am ET PLYMOUTH, Minn., July 07, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that it has ente... 
06/01/17Entellus Medical to Present at the William Blair Growth Stock Conference
PLYMOUTH, Minn., June 01, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced the Company plans to participate in the 37th Annual Growth Stock Conference hosted by William Blair in Chicago, IL. E... 
05/22/17The Centers for Medicare & Medicaid Services (CMS) Establishes Coding and Payment for Eustachian Tube Balloon Dilation
PLYMOUTH, Minn., May 22, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced that the CMS has established a unique billing code and payment for endoscopic balloon dilation to treat Eustachian tube d... 
05/03/17Entellus Medical Announces First Quarter 2017 Financial Results
PLYMOUTH, Minn., May 03, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ: ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter ended March 31, 2017.  Recent Highlights and Accomplishments Revenue of $19.1 million in the first quarter of 2017, an increase of 13% year-over-... 
04/20/17Entellus Medical to Present at the Deutsche Bank Annual Health Care Conference
PLYMOUTH, Minn., April 20, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced the Company plans to participate in the 42nd Annual Health Care Conference hosted by Deutsche Bank in Boston, MA. En... 
04/19/17Entellus Medical to Report First Quarter 2017 Financial Results on May 3, 2017
Conference call scheduled for Wednesday, May 3, 2017 at 3:30pm CT / 4:30pm ET PLYMOUTH, MN, April 19, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced that it will release its financial results ... 
04/12/17Entellus Medical Receives FDA 510(k) Clearance for Eustachian Tube Indication
PLYMOUTH, Minn., April 12, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the Company has received 510(k) clearance from the United States Food and Drug Administration (FDA) for use of its XprESS ENT Dilation System in patients with persistent Eustachian tube dysf... 
02/21/17Entellus Medical Announces Fourth Quarter and Full Year 2016 Financial Results
PLYMOUTH, Minn., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter and year ended December 31, 2016.  Recent Highlights and Accomplishments Revenue of $21.7 million in the fourth quarter of 2016, an increase of 2... 
02/01/17Entellus Medical to Report Fourth Quarter and Full Year 2016 Financial Results on February 21, 2017
Conference call scheduled for Tuesday, February 21, 2017 at 3:30pm CT / 4:30pm ET PLYMOUTH, Minn., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that it will release its financial results for the fourth quarter and full year 2016 after the close of tr... 
01/25/17Entellus Medical Announces Pricing of Public Offering of Common Stock
PLYMOUTH, Minn., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (the “Company” or “Entellus Medical”) (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients, today announced the pricing of its underwritten public offering of 3,530,000 shares of its common stock at a price of $17.00 per share before... 
01/25/17Entellus Medical Announces Proposed Public Offering of Common Stock
PLYMOUTH, Minn., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (the “Company” or “Entellus Medical”) (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients, today announced that it has commenced an underwritten public offering of $60.0 million of shares of its common stock. The offering is expecte... 
01/05/17Entellus Medical Announces Management Promotions and Preliminary Revenue for Fourth Quarter and Full Year 2016
PLYMOUTH, Minn., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the promotion of Thomas Williamson to the position of Vice President of Sales; the resignation of Jim Surek as Vice President of Sales, and the promotion of Jonelle Burnham to the position of...